Search

Your search keyword '"Cheema, Parneet"' showing total 4 results
Start Over Author "Cheema, Parneet" Journal journal of thoracic oncology
4 results on '"Cheema, Parneet"'

1. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Author

Camidge, D. Ross, Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Noe, Johannes, Nowicka, Malgorzata, Gadgeel, Shirish M., Cheema, Parneet, Pavlakis, Nick, de Marinis, Filippo, Cho, Byoung Chul, Zhang, Li, Moro-Sibilot, Denis, Liu, Ting, Bordogna, Walter, Balas, Bogdana, Müller, Barbara, and Shaw, Alice T.

Published
2019
Full Text
View/download PDF

3. PPD01.02 Repotrectinib in Patients With ROS1Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial

Author

Drilon, Alexander, Camidge, D. Ross, Lin, Jessica J., Kim, Sang-We, Solomon, Benjamin, Dziadziuszko, Rafal, Besse, Benjamin, Goto, Koichi, Johannes de Langen, Adrianus, Wolf, Jürgen, Lee, Ki Hyeong, Popat, Sanjay, Springfeld, Christoph, Nagasaka, Misako, Felip, Enriqueta, Yang, Nong, Lu, Shun, Kao, Steven, Velcheti, Vamsidhar, Cheema, Parneet, Stopatschinskaja, Shanna, Mehta, Minal, Trone, Denise, Ades, Felipe, Calvet, Christophe Y., and Cho, Byoung Chul

Published
2024
Full Text
View/download PDF

4. Updated Efficacy and Safety Data and Impact of the EML4-ALKFusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study

Author

Camidge, D. Ross, Dziadziuszko, Rafal, Peters, Solange, Mok, Tony, Noe, Johannes, Nowicka, Malgorzata, Gadgeel, Shirish M., Cheema, Parneet, Pavlakis, Nick, de Marinis, Filippo, Cho, Byoung Chul, Zhang, Li, Moro-Sibilot, Denis, Liu, Ting, Bordogna, Walter, Balas, Bogdana, Müller, Barbara, and Shaw, Alice T.

Abstract

At the prior data cutoff (February 9, 2017) the ALEX trial showed superior investigator-assessed progression-free survival (PFS) for alectinib versus crizotinib in untreated, anaplastic lymphoma kinase (ALK)-positive, advanced NSCLC (hazard ratio = 0.47, 95% confidence interval: 0.34–0.65, p< 0.001). The median PFS in the alectinib arm was not reached versus 11.1 months with crizotinib. Retrospective analyses suggest that the echinoderm microtubule-associated protein-like 4 gene-ALK variant (EML4-ALK) may influence ALK-inhibitor treatment benefit. We present updated analyses, including exploratory subgroup analysis by EML4-ALKvariant, after an additional 10 months’ follow-up (cutoff December 1, 2017).

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results